N-Methyl-1-(2-(naphthalen-1-ylthio)phenyl)methanamine hydrochloride
6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
2-(2,6-Difluorophenyl)-4-((4-(pyrrolidine-1-carbonyl)phenyl)amino)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one
(R)-2-((5-Methoxy-2-(methylamino)pyrimidin-4-yl)amino)hexan-1-ol
Anifrolumab
Sodium (5R,7R,8R,12aR,14R,15R,15aS,16R)-7-(2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)-14-(6-amino-9H-purin-9-yl)-15,16-dihydroxyoctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11]pentaoxa[2,10]diphosphacyclotetradecine-2,10-bis(olate) 2,10-dioxide
1-((4-(4-Fluorophenyl)-6-methoxy-2H-chromen-3-yl)methyl)pyrrolidine hydrochloride
4-(Benzyloxy)-3,3-diethyl-2H-benzo[g]indole-2,5(3H)-dione
N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
2-[2,4-Bis(trifluoromethyl)imidazo[1,2-a]1,8-naphthyridin-8-yl]-1,3,4-oxadiazole
EGFR-IN-11
Rontalizumab
Emapalumab (anti-IFNγ)
Sifalimumab
1-((S)-3-(3,4-Dichlorophenyl)piperidin-1-yl)-3-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)prop-2-yn-1-one
Dazukibart
Faralimomab
Monalizumab
ODN 1585
